These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 13375120)

  • 21. [Effect of the injection of saccharated iron oxide on the phagocytic activity of the reticuloendothelial system in the rat].
    BENACERRAF B; BIOZZI G; STIFFEL C
    C R Seances Soc Biol Fil; 1956 Nov; 150(6):1161-4. PubMed ID: 13383921
    [No Abstract]   [Full Text] [Related]  

  • 22. Hypophosphatemia induced by intravenous administration of Saccharated iron oxide.
    Okada M; Imamura K; Iida M; Fuchigami T; Omae T
    Klin Wochenschr; 1983 Jan; 61(2):99-102. PubMed ID: 6843038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The reticuloendothelial system in the rabbit. Phagocytosis of saccharated iron oxide.
    MOORE RD; RUPP J; MUMAW V; SCHOENBERG MD
    Arch Pathol; 1961 Jul; 72():51-60. PubMed ID: 13772347
    [No Abstract]   [Full Text] [Related]  

  • 24. Intravenous treatment of anaemia with an iron-sucrose preparation.
    SLACK HG; WILKINSON JF
    Lancet; 1949 Jan; 1(6540):11-4. PubMed ID: 18208026
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmacokinetics and utilization of iron sucrose.
    Danielson BG; Beshara S
    Am J Kidney Dis; 2003 Nov; 42(5):1104; author reply 1104-5. PubMed ID: 14582057
    [No Abstract]   [Full Text] [Related]  

  • 26. Iatrogenic osteomalacia caused by intravenous administration of saccharated ferric oxide.
    Suzuki A; Ohoike H; Matsuoka Y; Irimajiri S
    Am J Hematol; 1993 May; 43(1):75-6. PubMed ID: 8317471
    [No Abstract]   [Full Text] [Related]  

  • 27. Safety issues with iron sucrose.
    Fishbane S
    Am J Kidney Dis; 2003 Apr; 41(4):899; author reply 900. PubMed ID: 12666081
    [No Abstract]   [Full Text] [Related]  

  • 28. Reactivity of iron compounds.
    Geisser P
    Am J Kidney Dis; 2003 Nov; 42(5):1103-4. PubMed ID: 14582056
    [No Abstract]   [Full Text] [Related]  

  • 29. Use of i.v. iron saccharate in haemodialysis patients not responding to oral iron and erythropoietin.
    al-Hawas F; Abdalla AH; Popovich W; Mousa DH; al-Sulaiman MH; al-Khader AA
    Nephrol Dial Transplant; 1997 Dec; 12(12):2801-2. PubMed ID: 9430909
    [No Abstract]   [Full Text] [Related]  

  • 30. Intravenous iron sucrose: an alternative for oral iron in pregnancy with iron deficiency anemia.
    Shi Q; Li J; Yao Q; Mi C; Yang J; Xing A
    Ann Hematol; 2015 Mar; 94(3):523-5. PubMed ID: 25123238
    [No Abstract]   [Full Text] [Related]  

  • 31. Optimal Serum Ferritin Levels for Iron Deficiency Anemia during Oral Iron Therapy (OIT) in Japanese Hemodialysis Patients with Minor Inflammation and Benefit of Intravenous Iron Therapy for OIT-Nonresponders.
    Takasawa K; Takaeda C; Wada T; Ueda N
    Nutrients; 2018 Mar; 10(4):. PubMed ID: 29596361
    [No Abstract]   [Full Text] [Related]  

  • 32. Safety of high doses of non-dextran irons.
    Folkert VW
    Semin Dial; 2003; 16(3):285-6. PubMed ID: 12753696
    [No Abstract]   [Full Text] [Related]  

  • 33. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia.
    Shimizu Y; Tada Y; Yamauchi M; Okamoto T; Suzuki H; Ito N; Fukumoto S; Sugimoto T; Fujita T
    Bone; 2009 Oct; 45(4):814-6. PubMed ID: 19555782
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Response of omental milk spots to colloidal saccharated ferric oxide in the mouse: light and electron microscopic study (author's transl)].
    Takemori N; Ito T
    Hokkaido Igaku Zasshi; 1981 Mar; 56(2):199-216. PubMed ID: 7327509
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Continuity of research outcomes: the correlation of bench toxicity mechanisms to clinical outcomes--are they dependable?
    Oldham FB
    Am J Kidney Dis; 2002 Nov; 40(5):1109; author reply 1109. PubMed ID: 12407662
    [No Abstract]   [Full Text] [Related]  

  • 36. Ferumoxytol: an intravenous iron, riskier than iron sucrose.
    Prescrire Int; 2013 Sep; 22(141):206. PubMed ID: 24171212
    [No Abstract]   [Full Text] [Related]  

  • 37. The uptake of particulate matter by endothelial cells.
    Florey L
    Proc R Soc Lond B Biol Sci; 1967 Jan; 166(1005):375-83. PubMed ID: 24796034
    [No Abstract]   [Full Text] [Related]  

  • 38. [Iron saccharate tolerance tests].
    STILLE G
    Naunyn Schmiedebergs Arch Exp Pathol Pharmakol; 1953; 218(1-2):138-9. PubMed ID: 13087338
    [No Abstract]   [Full Text] [Related]  

  • 39. [The behavior of iron saccharates in the body and its therapeutic significance].
    PRIBILLA W
    Naunyn Schmiedebergs Arch Exp Pathol Pharmakol; 1953; 217(5):508-38. PubMed ID: 13087302
    [No Abstract]   [Full Text] [Related]  

  • 40. [Colorimetric determination of iron in colloid iron-saccharate solutions].
    OVERKAMP H
    Munch Med Wochenschr; 1952 Feb; 94(5):220-21. PubMed ID: 14919453
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.